Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Code effective Jan 01, 2022
HCPCS Section
Temporary Codes for Use with Outpatient Prospective Payment System
C9081 is a valid 2026 HCPCS code meaning Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose or (Idecabtagene car pos t) for short. HCPCS C9081 has been effective since 01/01/2022 and applies to Other medical items or services.
|
HCPCS Level II Code Section C - Temporary Codes for Use with Outpatient Prospective Payment System |
|
| HCPCS Code | C9081 |
|---|---|
| Description |
Long description:
Short description: |
| HCPCS Pricing indicator |
53 - Statute
|
| Multiple pricing indicator |
A - Not applicable as HCPCS priced under one methodology
|
| Statute number | 1833(t) |
| Coverage code | D - Special coverage instructions apply |
| BETOS2 code | O1D - Chemotherapy |
| HCPCS Action code | N - No maintenance for this code |
| Type of service | 9 - Other medical items or services |
| Effective date | Effective Jan 01, 2022 |
| Date added | Added Oct 01, 2021 |
| Termination date | Dec 31, 2021 |
1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).
2 BETOS stands for “Berenson-Eggers Type Of Service”
HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/23/2026
CPT® is a registered trademark of the American Medical Association (AMA). All rights reserved.